Table 1.
Clinico-demographic characteristics of sample across study arms.
| Active Control (n=30) | Goal Management Training (GMT) (n=30) | GMT + Metacognitive Training (n=30) | p-value | |
|---|---|---|---|---|
| Demographics | ||||
|
| ||||
| Age, y | 47.8 (11.6) | 50.1 (10.1) | 50.6 (9.2) | 0.56 |
| Education, y | 13.1 (2.9) | 13.5 (2.1) | 12.9 (2.8) | 0.69 |
| Sex (% M, n) | 86.7% (26) | 90.0% (27) | 90.0% (27) | 0.89 |
| Race (% White, n) | 56.7% (17) | 53.3% (16) | 56.7% (17) | 0.64 |
|
| ||||
| Substance Use | ||||
|
| ||||
| U-Tox Pos at Eval (%, n) | 36.7% (11) | 26.7% (8) | 20.0% (6) | 0.35 |
| Lifetime Substance Use Disorders (%, n) | ||||
| Alcohol | 75.0% (21) | 62.1% (18) | 79.3% (23) | 0.31 |
| Methamphetamine | 60.7% (17) | 44.8% (13) | 69.0% (20) | 0.17 |
| Cocaine | 46.4% (13) | 34.5% (10) | 32.1% (9) | 0.49 |
| Cannabis | 39.3% (11) | 41.4% (12) | 35.2% (10) | 0.91 |
| Opioid | 14.3% (4) | 6.9% (2) | 17.9% (5) | 0.45 |
| Polysubstance | 63.3% (19) | 60.0% (18) | 70.0% (21) | 0.71 |
| Any Current SUD (%, n) | 18.5% (5) | 14.3% (4) | 21.4% (6) | 0.78 |
| Any Substance Use in Last Year (%, n) | 70.0% (21) | 90.0% (27) | 70.0% (21) | 0.11 |
| Any Substance Last Use, days | 12.6 (27.1) | 20.5 (44.5) | 15.3 (39.7) | 0.80 |
|
| ||||
| HIV Disease | ||||
|
| ||||
| Nadir CD4 | 155 (29, 344.5) | 134 (39.5, 269) | 182 (15.5, 407) | 0.41 |
| Current CD4 | 588.5 (404, 857) | 489 (278.3, 642) | 552 (307, 867) | 0.26 |
| AIDS (%, n) | 66.7% (18) | 64.3% (18) | 55.2% (2) | 0.64 |
| Est. Duration Infection, y | 13.1 (20.8) | 15.5 (8.0) | 11.0 (7.9) | 0.50 |
| VL Detect (plasma; %, n) | 28.6% (6) | 38.9% (7) | 20.8% (5) | 0.44 |
| On ART (%, n) | 85.2% (23) | 92.9% (26) | 82.1% (23) | 0.48 |
| VL Detect on ART (%, n) | 23.5% (4) | 31.3% (5) | 15.8% (3) | 0.56 |
|
| ||||
| Psychiatric and Neurocognitive | ||||
|
| ||||
| BDI-II | 16.3 (11.2) | 10.8 (10.8) | 13.9 (13.4) | 0.27 |
| BDI-II≥17 (%, n) | 50.0% (12) | 24.0% (6) | 30.4% (7) | 0.14 |
| TEA Dual Srch Decr (ss) | 9.7 (4.5) | 10.0 (3.9) | 10.9 (4.2) | 0.52 |
| TEA Dual Srch Decr raw | ||||
| % below median | 46.7% (14) | 53.3% (16) | 50.0% (16) | 0.88 |
|
| ||||
| Comprehensive Neuropsychological (NP) Battery (prior parent study visit) | ||||
|
| ||||
| % Impaired | ||||
| Reason/Flexibility | 50.0% (14) | 48.3% (14) | 50.0% (15) | 0.99 |
| Working Memory | 32.0% (8) | 33.3% (9) | 46.4% (13) | 0.48 |
| Verbal Fluency | 42.3% (11) | 33.3% (9) | 41.4% (12) | 0.76 |
| Global NP | 64.3% (18) | 58.6% (17) | 73.3% (22) | 0.49 |
| Global NP Mean T | 43.3 (7.3) | 43.7 (5.3) | 42.9 (7.0) | 0.89 |
Note. U-Tox Positive at Eval=urine toxicology screen positive at evaluation; SUD=DSM-IV substance use disorder; AIDS=acquired immune deficiency syndrome; ART=antiretroviral therapy; TEA Dual Srch Decr=Test of Everyday Attention Dual Search Decrement.